Experimentally, navitoclax kills cells in a BAX/BAK-dependent method and leads to regression of lymphoid tumors in xenograft products. ). The density of α7-nAChRs is radically upregulated in the A/J lung and lung tumors although not in C3H lung tissue at 6 mo after NNK therapy (Figure 1A, middle panel Inbound https://messiahzjbn791537.blognody.com/25793284/a-review-of-navitoclax